Merck to buy vaccine plant from Wuxi Biologics

WuXi Biologics to Sell Irish Vaccine Facility to Merck for $500 Million
WuXi Biologics’ move to sell the facility could strengthen the company’s cash flow and margins as it navigates global uncertainties.
China's WuXi Biologics to sell Irish vaccine facility to Merck as US curbs loom
China's WuXi Biologics said on Monday it will sell its vaccine facility in Ireland to U.S. drugmaker Merck & Co for about $500 million, ahead of potential U.S. legislation that would restrict business for Chinese biotech companies.
In €500M deal, Merck buys Ireland vaccines plant from CDMO WuXi Biologics
In Ireland, WuXi Biologics has sold a new vaccines plant to Merck & Co. for €500 million ($521 million). The New Jersey company was a natural buyer of the facility as it was the lone client WuXi Biologics served at the site in Dundalk, executing a 20-year contract to produce vaccines worth $150 million annually.
Merck Snaps Up WuXi Biologics Facility in Ireland for $500M
The acquisition from Wuxi Biologics, the embattled CDMO named in the BIOSECURE Act, marks another expansion of Merck’s manufacturing operations in Ireland.
Merck to acquire WuXi Biologics Ireland vaccine facility for USD 500 million
China's WuXi Biologics has announced plans to sell its vaccine facility in Ireland to U.S. pharmaceutical giant Merck & Co. for approximately USD 500 million. The decision comes ahead of
China's WuXi Biologics to sell Irish vaccine facility to Merck for $500 million
China's WuXi Biologics said on Monday it will sell its vaccine facility in Ireland to U.S. drugmaker Merck & Co for about $500 million. The Financial Times had reported in October that WuXi and WuXi AppTec are planning to sell some of their operations,
WuXi Bio to Sell Vaccine Facility to Merck for $500 Million
WuXi Biologics Cayman Inc. will sell a vaccine facility in Ireland to Merck & Co. for about $500 million as the Chinese company seeks to enhance its margins while continuing to navigate geopolitical tensions.
China’s WuXi Biologics to sell vaccine facility to Merck for US$500 million
WUXI Biologics Cayman will sell a vaccine facility in Ireland to Merck for about US$500 million as the Chinese company seeks to enhance its margins while continuing to navigate geopolitical tensions.
Merck to buy WuXi Biologics' Irish vaccine facility for $500 million
WuXi Biologics, a Chinese biopharmaceuticals company, announced on Monday the sale of its WuXi Vaccines facility in Ireland to MSD International, a subsidiary of Merck & Co. for approximately $500 million.
China's WuXi Biologics to sell Irish vaccine facility to Merck for €500m
China's WuXi Biologics has confirmed it will sell its vaccine facility in Ireland to US drugmaker Merck & Co for about €500 million. The WuXi Biologics facility is located in Dundalk, Co Louth, in the IDA Science and Technology Park.
Merck to buy vaccine plant from WuXi Biologics: report
WuXi Biologics (OTCPK:WXIBF) is reportedly selling its vaccine facility in Ireland to Merck (NYSE:MRK) as part of a previously announced plan to divest some of its assets. The China-based contract research,
GEN16h
Candid Therapeutics Enters into Agreement with WuXi Biologics on Trispecific T-Cell Engager
WuXi upgraded its WuXiBody platform in bispecific antibody discovery to address the growing global demand for these complex ...
Wuxi Biologics upgraded to Overweight from Neutral at JPMorgan
JPMorgan upgraded Wuxi Biologics (WXXWY) to Overweight from Neutral with a price target of HK$20, up from HK$13, citing expected order growth ...